ArchPoint Investors’s Idexx Laboratories IDXX Stock Holding History

ArchPoint Investors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-356	Closed	-$221K	–	87
2021 Q3	$221K	Buy	+356	New	+$239K	0.07%	98

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ArchPoint Investors's IDXX Position: Q4 2021 in Review

ArchPoint Investors sold out of Idexx Laboratories (IDXX) in Q4 2021, closing a stake of 356 shares — an estimated $221K sold.

ArchPoint Investors first reported a position in IDXX in Q3 2021 and held it in 1 quarter. The position peaked at $221K in Q3 2021. 1,107 funds tracked by Wall St. Rank hold IDXX as of Q4 2021.

ArchPoint Investors reported no remaining Idexx Laboratories position as of Q4 2021 after selling out during the quarter.
ArchPoint Investors sold 356 Idexx Laboratories shares in Q4 2021, an estimated $221K.
ArchPoint Investors first reported a position in Idexx Laboratories in Q3 2021 and held it in 1 quarter.
ArchPoint Investors's Idexx Laboratories position peaked at $221K in Q3 2021.
1,107 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2021.

Based on ArchPoint Investors's 13F filing for Q4 2021, filed 11 Feb 2022.